INTERVIEW ▶▶▶ Sebastian Marten
“We are the world’s engine of enzyme development”
Just recently the renowned nutrition and health company DSM introduced the new enzyme Balancius onto the European market. “It’s the first enzyme targeting dead cells and unlocking their nutritional potential,” says DSM vice president Enzymes and Eubiotics Sebastian Marten. He continues: “This is an absolute breakthrough innovation and we are very bold about this.”
I BY FABIAN BROCKÖTTER
n the wake of DSM’s launch of it’s new enzyme Balancius at the European symposium on poultry nutrition in Gdanks, Poultry World sat down with Sebastian Marten. As vice presi- dent Enzymes and Eubiotics he oversees the companies inno-
vation programme and long term strategy. “As a leader in the field of animal nutrition and health, we are at the forefront of innova- tion and sustainability. That is what our customers and society as
“Making sure that broilers digest every gram of
nutrient is key in the quest for maximum sustainability.”
a whole demands from us and that is what is embedded in our DNA.” According to Mr Marten the company’s strategy for the next 5-10 years revolves around sustainability. “Many people said it before, but our industry has a tremendous challenge lying ahead. Feeding the ever growing hunger of the world, we face additional pressure on the limited natural resources. Improving efficiency and making sure that broilers digest every gram of nutrients
6 ▶ POULTRY WORLD | No. 6, 2019
they ingest is key in the quest for maximum sustainability.” More than two decades ago DSM realised that enzymes could play an important role in ensuring optimal performance of the bird’s digestive tract. It was then that they joined forces with No- vozymes, a world leader in bio-innovation. “This alliance sped things up as both partners exchanged their knowledge and exist- ing work. What was done, in essence, is that we looked at what we both had in the field of enzymes and looked at what was still out there.” Until now all enzyme products out there target living bacteria. Mr Marten: “That makes perfect sense, because in biolo- gy you are focused on making a difference for the living. An entire science was focused on the living and we too have a fantastic track record and product portfolio in place.” Mr Marten continues: “But, DSM is all about breakthrough innovations. You don’t
Balansius is the first enzyme that targets the so called peptidoglycans, bacterial cell debris.
PHOTO: ABERRATION FILMS LTD/SCIENCE PHOTO LIBRARY PHOTO: DSM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36
